NTMD könnte noch abgehen als DVAX,fetter DEAL - 500 Beiträge pro Seite
eröffnet am 23.12.08 12:29:01 von
neuester Beitrag 13.01.09 17:38:21 von
neuester Beitrag 13.01.09 17:38:21 von
Beiträge: 87
ID: 1.147.066
ID: 1.147.066
Aufrufe heute: 0
Gesamt: 9.379
Gesamt: 9.379
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| heute 19:46 | 6893 | |
| vor 53 Minuten | 5565 | |
| vor 1 Stunde | 4691 | |
| vor 1 Stunde | 4434 | |
| vor 29 Minuten | 3122 | |
| heute 19:32 | 2279 | |
| heute 14:53 | 1979 | |
| vor 1 Stunde | 1787 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.182,00 | +0,59 | 229 | |||
| 2. | 3. | 0,1935 | +0,78 | 96 | |||
| 3. | 2. | 1,1800 | -14,49 | 87 | |||
| 4. | 5. | 9,3575 | +0,27 | 60 | |||
| 5. | 4. | 157,63 | -1,36 | 55 | |||
| 6. | Neu! | 0,3050 | +4,63 | 38 | |||
| 7. | Neu! | 4,8025 | +6,45 | 34 | |||
| 8. | Neu! | 11,828 | +13,73 | 32 |
Feedback
könnte noch mehr abgehen als DVAX
On November 18, 2008, Archemix announced that it had entered into a merger agreement with NitroMed, Inc., (NASDAQ: NTMD) pursuant to which Archemix has agreed to merge with NitroMed in an all-share transaction. The merger is subject to approval by Archemix\'s and NitroMed\'s shareholders, consummation of the sale of NitroMed\'s BiDil and BiDil XR drug business and other customary closing conditions. As a result of the $27.5 million in upfront payments received by Archemix from GSK, Archemix now estimates that cash and cash equivalents for the combined company at the closing of the merger will be approximately $78-88 million.
Important Additional Information Will Be Filed with the SEC
In connection with Archemix’s proposed merger with NitroMed, NitroMed has filed with the SEC a Registration Statement on Form S-4 containing a joint proxy statement/prospectus. Once the Form S-4 is declared effective by the SEC, the joint proxy statement/prospectus will be mailed to shareholders of NitroMed and Archemix. The joint proxy statement/prospectus will contain important information about NitroMed, Archemix, the transaction and related matters. In addition, NitroMed has filed with the SEC and mailed to its shareholders a definitive proxy statement in connection with the previously-announced proposed sale of its BiDil and BiDil XR drug business to JHP Pharmaceuticals, LLC. The definitive proxy statement contains important information about NitroMed, the proposed sale of the BiDil and BiDil XR drug business and related matters. Investors and security holders of Archemix and NitroMed are urged to read carefully both the joint proxy statement/prospectus relating to the merger, when it is available, and the definitive proxy statement relating to the proposed sale of the BiDil and BiDil XR drug business.
Investors and security holders of Archemix will be able to obtain free copies of the joint proxy statement/prospectus for the merger (when it is available) by contacting Archemix Corp., Attn: Secretary, 300 Third Street, Cambridge, MA 02142. In addition, investors and security holders of NitroMed will be able to obtain free copies of the definitive proxy statement for the proposed sale of the BiDil and BiDil XR drug business and the joint proxy statement/prospectus for the proposed merger (when it is available), and other documents filed with the SEC by NitroMed through the website maintained by the SEC at www.sec.gov and also by contacting NitroMed, Inc., Attn: Secretary, 45 Hayden Avenue, Suite 3000, Lexington, MA 02421.
Archemix and NitroMed, and their respective directors and executive officers, may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the merger agreement with NitroMed. In addition, NitroMed, and its directors and executive officers, may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the purchase and sale agreement with JHP Pharmaceuticals relating to the sale of the BiDil and BiDil XR drug business. Information regarding NitroMed\'s directors and executive officers is contained in NitroMed\'s Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its proxy statement dated April 16, 2008, which are filed with the SEC. As of November 30, 2008, NitroMed\'s directors and executive officers beneficially owned approximately 33% of NitroMed\'s common stock. In addition, information regarding Archemix\'s directors and officers and a more complete deion of the interests of NitroMed\'s directors and officers will be available in the joint proxy statement/prospectus relating to the merger. A more complete deion of the interests of NitroMed\'s directors and officers is also available in the definitive proxy statement relating to the sale of the BiDil and BiDil XR drug business.
On November 18, 2008, Archemix announced that it had entered into a merger agreement with NitroMed, Inc., (NASDAQ: NTMD) pursuant to which Archemix has agreed to merge with NitroMed in an all-share transaction. The merger is subject to approval by Archemix\'s and NitroMed\'s shareholders, consummation of the sale of NitroMed\'s BiDil and BiDil XR drug business and other customary closing conditions. As a result of the $27.5 million in upfront payments received by Archemix from GSK, Archemix now estimates that cash and cash equivalents for the combined company at the closing of the merger will be approximately $78-88 million.
Important Additional Information Will Be Filed with the SEC
In connection with Archemix’s proposed merger with NitroMed, NitroMed has filed with the SEC a Registration Statement on Form S-4 containing a joint proxy statement/prospectus. Once the Form S-4 is declared effective by the SEC, the joint proxy statement/prospectus will be mailed to shareholders of NitroMed and Archemix. The joint proxy statement/prospectus will contain important information about NitroMed, Archemix, the transaction and related matters. In addition, NitroMed has filed with the SEC and mailed to its shareholders a definitive proxy statement in connection with the previously-announced proposed sale of its BiDil and BiDil XR drug business to JHP Pharmaceuticals, LLC. The definitive proxy statement contains important information about NitroMed, the proposed sale of the BiDil and BiDil XR drug business and related matters. Investors and security holders of Archemix and NitroMed are urged to read carefully both the joint proxy statement/prospectus relating to the merger, when it is available, and the definitive proxy statement relating to the proposed sale of the BiDil and BiDil XR drug business.
Investors and security holders of Archemix will be able to obtain free copies of the joint proxy statement/prospectus for the merger (when it is available) by contacting Archemix Corp., Attn: Secretary, 300 Third Street, Cambridge, MA 02142. In addition, investors and security holders of NitroMed will be able to obtain free copies of the definitive proxy statement for the proposed sale of the BiDil and BiDil XR drug business and the joint proxy statement/prospectus for the proposed merger (when it is available), and other documents filed with the SEC by NitroMed through the website maintained by the SEC at www.sec.gov and also by contacting NitroMed, Inc., Attn: Secretary, 45 Hayden Avenue, Suite 3000, Lexington, MA 02421.
Archemix and NitroMed, and their respective directors and executive officers, may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the merger agreement with NitroMed. In addition, NitroMed, and its directors and executive officers, may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the purchase and sale agreement with JHP Pharmaceuticals relating to the sale of the BiDil and BiDil XR drug business. Information regarding NitroMed\'s directors and executive officers is contained in NitroMed\'s Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its proxy statement dated April 16, 2008, which are filed with the SEC. As of November 30, 2008, NitroMed\'s directors and executive officers beneficially owned approximately 33% of NitroMed\'s common stock. In addition, information regarding Archemix\'s directors and officers and a more complete deion of the interests of NitroMed\'s directors and officers will be available in the joint proxy statement/prospectus relating to the merger. A more complete deion of the interests of NitroMed\'s directors and officers is also available in the definitive proxy statement relating to the sale of the BiDil and BiDil XR drug business.
bin dabei 
Antwort auf Beitrag Nr.: 36.258.472 von eula am 23.12.08 13:24:35ÄÄHMMM die meldung ist bereits einige tage alt...was soll da noch passieren 
GlaxoSmithKline and Archemix Form Strategic Alliance to Develop Aptamers to Treat Inflammatory Diseases
Last update: 2:30 a.m. EST Dec. 23, 2008
LONDON, Dec 23, 2008 (BUSINESS WIRE) -- GlaxoSmithKline and Archemix Corp. today announced a worldwide strategic alliance to discover, develop and commercialise aptamer therapeutics to treat inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease. Aptamers are synthetised oligonucleotides, or short nucleic acid sequences, that bind to proteins with high affinity and specificity.
The alliance leverages Archemix's unique expertise and intellectual property position in the discovery and development of aptamer therapeutics and provides GSK with an option to license product candidates directed at seven different aptamer targets with relevance in inflammatory disease.
Under the terms of the agreement, Archemix will receive $27.5 million in upfront payments from GSK, including a $6.5 million equity investment by GSK in the company. Archemix could also be eligible to receive up to $200 million in development, regulatory and sales milestone payments for each of the seven aptamer therapeutics which may be discovered and developed as part of the alliance. Archemix would also receive tiered royalties up to lower double digits on worldwide sales of products that may result from the alliance.
"We are very excited about this collaboration with GSK. GSK is an outstanding partner with leadership and expertise in inflammation, and we look forward to expanding our efforts in inflammation where aptamers could offer novel options to treat disease," said Errol DeSouza, Ph.D., President and Chief Executive Officer of Archemix. "This is another step forward in our strategy to leverage our intellectual property estate together with our significant internal capabilities in order to develop aptamers for a variety of therapeutic areas with key partners who are experts in their field."
Archemix will be responsible for the discovery and development of the aptamer therapeutics through completion of clinical proof of mechanism, unless GSK chooses to exercise its option earlier. After exercise of the option, GSK will have an exclusive license to drug product candidates developed under each programme by Archemix for the relevant aptamer target for further development and commercialisation on a worldwide basis. Archemix will have the right to further develop and commercialise any aptamer therapeutics which GSK chooses not to develop or commercialise.
"This innovative multi-target drug-discovery deal is an important extension of our externalisation strategy and provides GSK with an outstanding opportunity to work with the world leader in aptamer discovery and development," said Jose Carlos Gutierrez-Ramos, PhD., Senior Vice President and Head of the Immuno-Inflammation Centre of Excellence for Drug Discovery in GSK. "The application of aptamers with their unique properties is an exciting opportunity that holds enormous potential for the treatment of many devastating diseases of the immune system."
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
Aptamers are synthetically-derived oligonucleotides, or short nucleic acid sequences, that bind to protein targets with high affinity and specificity and can be designed to have a specified duration of action. Aptamers represent an emerging class of potential therapeutic agents that Archemix believes may have broad application to treat a variety of human diseases.
Archemix - is a biotechnology company focused on discovering, developing and commercialising aptamer therapeutics. Using Archemix's processes for discovering aptamers, which are protected by its broad patent portfolio, Archemix is developing aptamer product candidates for rare haematological diseases. In addition, Archemix has licensed its intellectual property to third parties to develop their own aptamer product candidates in other areas. Currently, Archemix's licensees are evaluating five different aptamer product candidates in human clinical trials; two in Phase 2 and three in Phase 1. Archemix has additional partnerships with several pharmaceutical and biotechnology companies, including Merck Serono, Pfizer, Takeda, Eli Lilly and Isis Pharmaceuticals.
On November 18, 2008, Archemix announced that it had entered into a merger agreement with NitroMed, Inc., (NTMD:
nitromed inc com
NTMD 0.35, +0.03, +9.4%) pursuant to which Archemix has agreed to merge with NitroMed in an all-share transaction. The merger is subject to approval by Archemix's and NitroMed's shareholders, consummation of the sale of NitroMed's BiDil and BiDil XR drug business and other customary closing conditions. As a result of the $27.5 million in upfront payments received by Archemix from GSK, Archemix now estimates that cash and cash equivalents for the combined company at the closing of the merger will be approximately $78-88 million.
Important Additional Information Will Be Filed with the SEC
In connection with Archemix's proposed merger with NitroMed, NitroMed has filed with the SEC a Registration Statement on Form S-4 containing a joint proxy statement/prospectus. Once the Form S-4 is declared effective by the SEC, the joint proxy statement/prospectus will be mailed to shareholders of NitroMed and Archemix. The joint proxy statement/prospectus will contain important information about NitroMed, Archemix, the transaction and related matters. In addition, NitroMed has filed with the SEC and mailed to its shareholders a definitive proxy statement in connection with the previously-announced proposed sale of its BiDil and BiDil XR drug business to JHP Pharmaceuticals, LLC. The definitive proxy statement contains important information about NitroMed, the proposed sale of the BiDil and BiDil XR drug business and related matters. Investors and security holders of Archemix and NitroMed are urged to read carefully both the joint proxy statement/prospectus relating to the merger, when it is available, and the definitive proxy statement relating to the proposed sale of the BiDil and BiDil XR drug business.
Investors and security holders of Archemix will be able to obtain free copies of the joint proxy statement/prospectus for the merger (when it is available) by contacting Archemix Corp., Attn: Secretary, 300 Third Street, Cambridge, MA 02142. In addition, investors and security holders of NitroMed will be able to obtain free copies of the definitive proxy statement for the proposed sale of the BiDil and BiDil XR drug business and the joint proxy statement/prospectus for the proposed merger (when it is available), and other documents filed with the SEC by NitroMed through the website maintained by the SEC at www.sec.gov and also by contacting NitroMed, Inc., Attn: Secretary, 45 Hayden Avenue, Suite 3000, Lexington, MA 02421.
Archemix and NitroMed, and their respective directors and executive officers, may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the merger agreement with NitroMed. In addition, NitroMed, and its directors and executive officers, may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the purchase and sale agreement with JHP Pharmaceuticals relating to the sale of the BiDil and BiDil XR drug business. Information regarding NitroMed's directors and executive officers is contained in NitroMed's Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its proxy statement dated April 16, 2008, which are filed with the SEC. As of November 30, 2008, NitroMed's directors and executive officers beneficially owned approximately 33% of NitroMed's common stock. In addition, information regarding Archemix's directors and officers and a more complete description of the interests of NitroMed's directors and officers will be available in the joint proxy statement/prospectus relating to the merger. A more complete description of the interests of NitroMed's directors and officers is also available in the definitive proxy statement relating to the sale of the BiDil and BiDil XR drug business.
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2007.
SOURCE: Archemix
For GSK:
UK Media enquiries:
Philip Thomson, (020) 8047 5502
or
Alice Hunt, (020) 8047 5502
or
Stephen Rea, (020) 8047 5502
or
US Media enquiries:
Nancy Pekarek, 919-483-2839
or
Mary Anne Rhyne, 919-483-2839
Last update: 2:30 a.m. EST Dec. 23, 2008
LONDON, Dec 23, 2008 (BUSINESS WIRE) -- GlaxoSmithKline and Archemix Corp. today announced a worldwide strategic alliance to discover, develop and commercialise aptamer therapeutics to treat inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease. Aptamers are synthetised oligonucleotides, or short nucleic acid sequences, that bind to proteins with high affinity and specificity.
The alliance leverages Archemix's unique expertise and intellectual property position in the discovery and development of aptamer therapeutics and provides GSK with an option to license product candidates directed at seven different aptamer targets with relevance in inflammatory disease.
Under the terms of the agreement, Archemix will receive $27.5 million in upfront payments from GSK, including a $6.5 million equity investment by GSK in the company. Archemix could also be eligible to receive up to $200 million in development, regulatory and sales milestone payments for each of the seven aptamer therapeutics which may be discovered and developed as part of the alliance. Archemix would also receive tiered royalties up to lower double digits on worldwide sales of products that may result from the alliance.
"We are very excited about this collaboration with GSK. GSK is an outstanding partner with leadership and expertise in inflammation, and we look forward to expanding our efforts in inflammation where aptamers could offer novel options to treat disease," said Errol DeSouza, Ph.D., President and Chief Executive Officer of Archemix. "This is another step forward in our strategy to leverage our intellectual property estate together with our significant internal capabilities in order to develop aptamers for a variety of therapeutic areas with key partners who are experts in their field."
Archemix will be responsible for the discovery and development of the aptamer therapeutics through completion of clinical proof of mechanism, unless GSK chooses to exercise its option earlier. After exercise of the option, GSK will have an exclusive license to drug product candidates developed under each programme by Archemix for the relevant aptamer target for further development and commercialisation on a worldwide basis. Archemix will have the right to further develop and commercialise any aptamer therapeutics which GSK chooses not to develop or commercialise.
"This innovative multi-target drug-discovery deal is an important extension of our externalisation strategy and provides GSK with an outstanding opportunity to work with the world leader in aptamer discovery and development," said Jose Carlos Gutierrez-Ramos, PhD., Senior Vice President and Head of the Immuno-Inflammation Centre of Excellence for Drug Discovery in GSK. "The application of aptamers with their unique properties is an exciting opportunity that holds enormous potential for the treatment of many devastating diseases of the immune system."
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
Aptamers are synthetically-derived oligonucleotides, or short nucleic acid sequences, that bind to protein targets with high affinity and specificity and can be designed to have a specified duration of action. Aptamers represent an emerging class of potential therapeutic agents that Archemix believes may have broad application to treat a variety of human diseases.
Archemix - is a biotechnology company focused on discovering, developing and commercialising aptamer therapeutics. Using Archemix's processes for discovering aptamers, which are protected by its broad patent portfolio, Archemix is developing aptamer product candidates for rare haematological diseases. In addition, Archemix has licensed its intellectual property to third parties to develop their own aptamer product candidates in other areas. Currently, Archemix's licensees are evaluating five different aptamer product candidates in human clinical trials; two in Phase 2 and three in Phase 1. Archemix has additional partnerships with several pharmaceutical and biotechnology companies, including Merck Serono, Pfizer, Takeda, Eli Lilly and Isis Pharmaceuticals.
On November 18, 2008, Archemix announced that it had entered into a merger agreement with NitroMed, Inc., (NTMD:
nitromed inc com
NTMD 0.35, +0.03, +9.4%) pursuant to which Archemix has agreed to merge with NitroMed in an all-share transaction. The merger is subject to approval by Archemix's and NitroMed's shareholders, consummation of the sale of NitroMed's BiDil and BiDil XR drug business and other customary closing conditions. As a result of the $27.5 million in upfront payments received by Archemix from GSK, Archemix now estimates that cash and cash equivalents for the combined company at the closing of the merger will be approximately $78-88 million.
Important Additional Information Will Be Filed with the SEC
In connection with Archemix's proposed merger with NitroMed, NitroMed has filed with the SEC a Registration Statement on Form S-4 containing a joint proxy statement/prospectus. Once the Form S-4 is declared effective by the SEC, the joint proxy statement/prospectus will be mailed to shareholders of NitroMed and Archemix. The joint proxy statement/prospectus will contain important information about NitroMed, Archemix, the transaction and related matters. In addition, NitroMed has filed with the SEC and mailed to its shareholders a definitive proxy statement in connection with the previously-announced proposed sale of its BiDil and BiDil XR drug business to JHP Pharmaceuticals, LLC. The definitive proxy statement contains important information about NitroMed, the proposed sale of the BiDil and BiDil XR drug business and related matters. Investors and security holders of Archemix and NitroMed are urged to read carefully both the joint proxy statement/prospectus relating to the merger, when it is available, and the definitive proxy statement relating to the proposed sale of the BiDil and BiDil XR drug business.
Investors and security holders of Archemix will be able to obtain free copies of the joint proxy statement/prospectus for the merger (when it is available) by contacting Archemix Corp., Attn: Secretary, 300 Third Street, Cambridge, MA 02142. In addition, investors and security holders of NitroMed will be able to obtain free copies of the definitive proxy statement for the proposed sale of the BiDil and BiDil XR drug business and the joint proxy statement/prospectus for the proposed merger (when it is available), and other documents filed with the SEC by NitroMed through the website maintained by the SEC at www.sec.gov and also by contacting NitroMed, Inc., Attn: Secretary, 45 Hayden Avenue, Suite 3000, Lexington, MA 02421.
Archemix and NitroMed, and their respective directors and executive officers, may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the merger agreement with NitroMed. In addition, NitroMed, and its directors and executive officers, may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the purchase and sale agreement with JHP Pharmaceuticals relating to the sale of the BiDil and BiDil XR drug business. Information regarding NitroMed's directors and executive officers is contained in NitroMed's Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its proxy statement dated April 16, 2008, which are filed with the SEC. As of November 30, 2008, NitroMed's directors and executive officers beneficially owned approximately 33% of NitroMed's common stock. In addition, information regarding Archemix's directors and officers and a more complete description of the interests of NitroMed's directors and officers will be available in the joint proxy statement/prospectus relating to the merger. A more complete description of the interests of NitroMed's directors and officers is also available in the definitive proxy statement relating to the sale of the BiDil and BiDil XR drug business.
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2007.
SOURCE: Archemix
For GSK:
UK Media enquiries:
Philip Thomson, (020) 8047 5502
or
Alice Hunt, (020) 8047 5502
or
Stephen Rea, (020) 8047 5502
or
US Media enquiries:
Nancy Pekarek, 919-483-2839
or
Mary Anne Rhyne, 919-483-2839
Trading Spotlight
Antwort auf Beitrag Nr.: 36.258.552 von Chessmaster am 23.12.08 13:35:52die Meldung ist komplett frisch, vielleicht solltest Du dich mal besser informieren.
Antwort auf Beitrag Nr.: 36.258.684 von MagicWeasel am 23.12.08 13:54:20
habe erneut die gesamte nachricht gestellt..
habe erneut die gesamte nachricht gestellt..
Antwort auf Beitrag Nr.: 36.258.695 von eula am 23.12.08 13:56:19sorry, da ist bei mir irgendwas rausgeflogen.
Danke nochmals
Danke nochmals
news sieht prächtig aus. bin auch mal auf einen trade rein. hier sind unter umständen mal schnelle 500% an einem tag drin wenn es gut läuft. gewissheit was passieren wird haben wir erst wenn die drüben auf machen. nur so lange wollte ich nicht warten. denn wenn das ding einmal los rennt ist es zu spät um vernünftig zu kaufen.
so würde sagen jetzt zurück lehnen und genießen...
so würde sagen jetzt zurück lehnen und genießen...
NitroMed und Archemix. Zusammenschluss ist seit dem 18. Bekannt ...
Wo steckt da noch Potenzial ??? Alte Meldung Neu aufbereitet nett man so was !!!
Vielleicht habt Ihr ja Glück und es fallen noch paar Doofe drauf rein!
Viel Glück!
Wo steckt da noch Potenzial ??? Alte Meldung Neu aufbereitet nett man so was !!!
Vielleicht habt Ihr ja Glück und es fallen noch paar Doofe drauf rein!
Viel Glück!
Hier die NEWS!
GlaxoSmithKline and Archemix Form Strategic Alliance to Develop Aptamers to Treat Inflammatory DiseasesLast
update: 12/23/2008 2:30:01 AM
http://custom.marketwatch.com/custom/tdameritrade-com/html-s…
GruSs BarfuSs
GlaxoSmithKline and Archemix Form Strategic Alliance to Develop Aptamers to Treat Inflammatory DiseasesLast
update: 12/23/2008 2:30:01 AM
http://custom.marketwatch.com/custom/tdameritrade-com/html-s…
GruSs BarfuSs
Hallo Eula,schon lange nichts mehr voneinander gelesen,das letzte mal bei Solargiga
Hab mir von eurer Perle auch mal ne Zockerposi gegönnt!
Grüssle und viel Glück@all
Hab mir von eurer Perle auch mal ne Zockerposi gegönnt!
Grüssle und viel Glück@all
Antwort auf Beitrag Nr.: 36.258.909 von Biotechspezialx am 23.12.08 14:29:58na wenn du das sagst: aber ist es nciht immer so die blöden kaufen als letztes ein. so läuft börse nunmal.... da hast du schon recht. nur hier wird es erst mal nett hoch gehen. schau hin was gleich passiert wenn die drüben auf machen. und hier wird das bid auch schon größer ist doch super. schönes weihnachtsgeschenk
Antwort auf Beitrag Nr.: 36.258.954 von julic26 am 23.12.08 14:36:32Hallo , julic26..
Habe mir noch mal den ersten Teil durch gelesen! Erinnert mich irgend wie an Point T. und Dara..
Wenn sich da was tun sollte hätte man gleich heute Morgen Reagieren müssen und umhauen tut mich der Deal ehrlich gesagt auf dem Gebiet nicht!
Aber wer weiß derzeit stützt sich alles in einer Stunde auf das Ding ..eine Stunde später sind alle wieder raus. Wenn hier rein und bei Gewinnen sofort wieder raus ist hier angesagt!
Wenn sich da was tun sollte hätte man gleich heute Morgen Reagieren müssen und umhauen tut mich der Deal ehrlich gesagt auf dem Gebiet nicht!
Aber wer weiß derzeit stützt sich alles in einer Stunde auf das Ding ..eine Stunde später sind alle wieder raus. Wenn hier rein und bei Gewinnen sofort wieder raus ist hier angesagt!
Antwort auf Beitrag Nr.: 36.258.983 von Biotechspezialx am 23.12.08 14:40:20ja so ist es. wenn es sehr gut läuft bis morgen mittag drin bleiben wenn das kaufverhalten drüben heute schon nicht 4-600% zulässt heute abend noch raus. so ist es. in diesen zeiten die sicherste art an der börse geld zu verdienen.
45min. noch dann wissen wir mehr
45min. noch dann wissen wir mehr
Antwort auf Beitrag Nr.: 36.258.958 von Imperator7 am 23.12.08 14:37:14Du hast schon recht! Das Ding hier schau ich mir mal von der Außenliene an .
Aber ich gönne es jedem wenn es hier gut laufen sollte.
Drücke Euch auf jeden Fall die Daumen das es ein Fettes Weihnachtgeschenk gibt und gut läuft!!
Aber ich gönne es jedem wenn es hier gut laufen sollte.
Drücke Euch auf jeden Fall die Daumen das es ein Fettes Weihnachtgeschenk gibt und gut läuft!!
Antwort auf Beitrag Nr.: 36.259.019 von Biotechspezialx am 23.12.08 14:44:46Weihnachtgeschenk
Antwort auf Beitrag Nr.: 36.259.008 von Imperator7 am 23.12.08 14:43:19Sage derzeit es sind echt total bekloppte Zeiten
...in einer Minute haste einen 5 Stelligen Betrag gewonnen ..2 Min, später einen 4 Stelligen verloren.
Alle spielen total verrückt derzeit!
...in einer Minute haste einen 5 Stelligen Betrag gewonnen ..2 Min, später einen 4 Stelligen verloren.
Alle spielen total verrückt derzeit!
Glaxo gets aptamer drug options in Archemix deal
Tue Dec 23, 2008 8:39am EST
http://www.reuters.com/article/marketsNews/idINLN51328120081…
* Glaxo can license specified inflammatory drugs
* Pact covers drugs developed using aptamer technology
* Archemix gets $27.5 mln, and up to $200 mln in milestones
* Archemix lined up to merge with NitroMed
LONDON, Dec 23 (Reuters) - GlaxoSmithKline (GSK.L) has secured options to license a number of drug candidates for inflammatory diseases after signing a development pact with U.S.-based Archemix it said on Tuesday.
Privately held Archemix, which is poised to merge with U.S. heart drug company NitroMed (NTMD.O), specialises in so-called aptamer technology, which tackles diseases by binding to proteins.
Under the deal with Glaxo, which covers a number of proteins linked to inflammatory diseases such as arthritis and inflammatory bowel disease, Archemix gets a $27.5 million upfront payment and up to $200 million in milestones.
Archemix has agreements with a number of major pharmaceutical companies, including Pfizer (PFE.N) and Eli Lilly (LLY.N), for treatments in a range of disease areas using its aptamer technology. (Reporting by Ben Deighton; Editing by Hans Peters)
Tue Dec 23, 2008 8:39am EST
http://www.reuters.com/article/marketsNews/idINLN51328120081…
* Glaxo can license specified inflammatory drugs
* Pact covers drugs developed using aptamer technology
* Archemix gets $27.5 mln, and up to $200 mln in milestones
* Archemix lined up to merge with NitroMed
LONDON, Dec 23 (Reuters) - GlaxoSmithKline (GSK.L) has secured options to license a number of drug candidates for inflammatory diseases after signing a development pact with U.S.-based Archemix it said on Tuesday.
Privately held Archemix, which is poised to merge with U.S. heart drug company NitroMed (NTMD.O), specialises in so-called aptamer technology, which tackles diseases by binding to proteins.
Under the deal with Glaxo, which covers a number of proteins linked to inflammatory diseases such as arthritis and inflammatory bowel disease, Archemix gets a $27.5 million upfront payment and up to $200 million in milestones.
Archemix has agreements with a number of major pharmaceutical companies, including Pfizer (PFE.N) and Eli Lilly (LLY.N), for treatments in a range of disease areas using its aptamer technology. (Reporting by Ben Deighton; Editing by Hans Peters)
fra
0,42
+85,02%
0,42
+85,02%
0,42hoffentlich erst der Anfang
Antwort auf Beitrag Nr.: 36.259.160 von eula am 23.12.08 15:03:08RT: fra 0,42€
wahnsinn hoffentlich richtiges gefühl gehabt. gleich geht es drüben los. mal sehen wie weit wir es dann bringen. bin jedenfalls schon nett im grünen. der frühe vogel fängt den wurm
wünsche uns allen einen super börsenstart in übersee
wahnsinn hoffentlich richtiges gefühl gehabt. gleich geht es drüben los. mal sehen wie weit wir es dann bringen. bin jedenfalls schon nett im grünen. der frühe vogel fängt den wurm
wünsche uns allen einen super börsenstart in übersee
Habe mir jetzt mal EPIX Pharmaceuticals gegönnt..
Lassen wir die beiden heute mal gegen einander antreten!
Mal schauen wer die Nase heute vorne hat!???
Lassen wir die beiden heute mal gegen einander antreten!
Mal schauen wer die Nase heute vorne hat!???
Wichtiger Hinweis
info
Börsenhandelszeiten an den Feiertagen
24.12. Deutschland: kein Handel; USA: 15:30-19:00 Uhr
25.12. Deutschland: kein Handel; USA: kein Handel
26.12. Deutschland: kein Handel; USA: 15:30-22:00 Uhr
30.12. Deutschland : 09:00-14:00 Uhr; USA: 15:30-22:00 Uhr
31.12. Deutschland: kein Handel; USA: 15:30-19:00 Uhr
01.01. Deutschland: kein Handel; USA: kein Handel
info
Börsenhandelszeiten an den Feiertagen
24.12. Deutschland: kein Handel; USA: 15:30-19:00 Uhr
25.12. Deutschland: kein Handel; USA: kein Handel
26.12. Deutschland: kein Handel; USA: 15:30-22:00 Uhr
30.12. Deutschland : 09:00-14:00 Uhr; USA: 15:30-22:00 Uhr
31.12. Deutschland: kein Handel; USA: 15:30-19:00 Uhr
01.01. Deutschland: kein Handel; USA: kein Handel
Fr0,49
Antwort auf Beitrag Nr.: 36.259.201 von Biotechspezialx am 23.12.08 15:10:58die war gesterns gut aber heute ist das schon ein heißes ding da ein zu steigen. mal sehen wer am ende heute vorne liegt.
hier in frankfurt geht ja schon gut was ab. das bid immer schön gefüllt und zieht mit.
noch 12 min. und die party beginnt
hier in frankfurt geht ja schon gut was ab. das bid immer schön gefüllt und zieht mit.
noch 12 min. und die party beginnt
Nasdaq Official Close Price/Date
$ .35 / Dec 22, 2008
$ .35 / Dec 22, 2008
Antwort auf Beitrag Nr.: 36.259.254 von Imperator7 am 23.12.08 15:17:17Komm halte die Wette dagegen! Wir schauen mal wer heute den besseren schnitt macht.
Also hältst du die Wette???
EPIX Pharmaceuticals, Inc.
(NasdaqGM: EPIX)
NEW Pre-market Real-time: 1.49 0.29 (+24.17%
Also hältst du die Wette???
EPIX Pharmaceuticals, Inc.
(NasdaqGM: EPIX)
NEW Pre-market Real-time: 1.49 0.29 (+24.17%
Antwort auf Beitrag Nr.: 36.259.306 von Biotechspezialx am 23.12.08 15:23:17ja ok halte dagegen. es kann nur einen geben
Antwort auf Beitrag Nr.: 36.259.315 von Imperator7 am 23.12.08 15:24:33Guter Mann!!! Sehr schön!!
Gewinne ja eh....
Gewinne ja eh....
NASDAQ Last Sale
0.6901
0.34 97.14%
0.6901
0.34 97.14%
!
Dieser Beitrag wurde moderiert. Grund: themenfremder Inhalt
Antwort auf Beitrag Nr.: 36.259.380 von Biotechspezialx am 23.12.08 15:32:07wir hier auch. RT: 0,76 usd
!
Dieser Beitrag wurde moderiert.
0,83 US-Dollar = 0,595067393 €
über 0,8 usdollar rockt das Ding erst richtig
Zieh an
Zieh an
!
Dieser Beitrag wurde moderiert.
10:04:20 $ .60 10,000
!
Dieser Beitrag wurde moderiert.
Antwort auf Beitrag Nr.: 36.259.520 von Biotechspezialx am 23.12.08 15:50:14hier kämpfen wir jetzt schon gegen die 0,6usd an. die sollten schon halten.
bis jetzt aber weitaus weniger als ich erwartet habe von den usa. ok zum schluss kaufen sie immer noch mal hoch aber bis dahin sollte das ding schon noch über der 0,6usd marke stehen sonst bringt auch der schlussspurt nichts mehr
bis jetzt aber weitaus weniger als ich erwartet habe von den usa. ok zum schluss kaufen sie immer noch mal hoch aber bis dahin sollte das ding schon noch über der 0,6usd marke stehen sonst bringt auch der schlussspurt nichts mehr !
Dieser Beitrag wurde moderiert.
10:11:51 $ .55 20,000
!
Dieser Beitrag wurde moderiert.
so hast gewonnen die 0,6wurde unterschritten. schlechtes zeichen. bin raus. knapp 25% gewinn sind besser als nichts. habe mir zwar weit mehr erhofft aber na gut kann ich mit leben.
mal sehen vielleicht komm ich später noch mal rein
mal sehen vielleicht komm ich später noch mal rein
ach du scheisse jetzt kämpft sie schon gegen die 0,5usd. da bin ich ja noch mal rechtzeitig raus
wie gesagt besser 25% als gleich ohne gewinne nach hause gehen. schade dachte die news bringt mehr
wie gesagt besser 25% als gleich ohne gewinne nach hause gehen. schade dachte die news bringt mehr
DOW am TT
!
Dieser Beitrag wurde moderiert. Grund: Spammposting!
Dieser Beitrag wurde moderiert. Grund: Spammposting
Antwort auf Beitrag Nr.: 36.259.780 von Imperator7 am 23.12.08 16:19:2925 % sind doch auch super!
Die Meldung liest sich auch nicht schlecht!
Kenne diesen Wirkstoff und halte Ihn nicht für Zukunftsreich.
Anscheinend wir diese Meinung auch so von größeren Investoren so gesehen!
Nicht alles in diesem Sektor Biotechs liest sich zwar ähnlich aber da stecken unterschiedliche Informationen dahinter!
Die Meldung liest sich auch nicht schlecht!
Kenne diesen Wirkstoff und halte Ihn nicht für Zukunftsreich.
Anscheinend wir diese Meinung auch so von größeren Investoren so gesehen!
Nicht alles in diesem Sektor Biotechs liest sich zwar ähnlich aber da stecken unterschiedliche Informationen dahinter!
Düne umsätze .. naya vor feiertag auch normal..
gap werd bestimmt heute nicht mehr geschlossen..
könnte wider up gehen..
bleibe weiter drin..
gap werd bestimmt heute nicht mehr geschlossen..
könnte wider up gehen..
bleibe weiter drin..
Volume
554,762
554,762
10:46:36 $ .57 15,389
Flynn James E- Insider Trading-DWAX hat alles verkauft..
Flynn James E- Insider Trading- NTMD-#Shares Total-3,580,090
http://www.sec.gov/Archives/edgar/data/927829/00011938050800…
Flynn James E- Insider Trading- NTMD-#Shares Total-3,580,090
http://www.sec.gov/Archives/edgar/data/927829/00011938050800…
die umsätze sind allerdings enttäuschend...
Antwort auf Beitrag Nr.: 36.260.213 von infight am 23.12.08 17:16:51werde es interessant ab nächste jahr..
ich behalte meine posi durch feiertage..vielleicht auch langfristig..
ich behalte meine posi durch feiertage..vielleicht auch langfristig..
Hier gehts erst los, stay tuned !
DRM.
DRM.
kann mir einer mal kurz erläutern worum es hier geht?
mein englisch ist nicht so gut.
mein englisch ist nicht so gut.
Antwort auf Beitrag Nr.: 36.260.926 von ottifant29 am 23.12.08 18:41:44billiger push die typischen wo bande ist vollzählig dabei
bedient 0,32 .. die stücke gehören langfristig in depot meine tochter..
Antwort auf Beitrag Nr.: 36.261.212 von eula am 23.12.08 19:23:24sehr schön....
ist ja nicht grade viel handel.
sehr dünne umsätze.
bin gespannt auf die schlussauktion
sehr dünne umsätze.
bin gespannt auf die schlussauktion
wird wohl auf tagestief enden
gap geschlossen!!
US-Handel
morgen
(verkürzt): 15.30h-19.00h
2. Weihnachtstag (26.12)
gibt es in USA nicht
-> nomaler Handel 15.30h-22.00h !!!!!
Gute Nacht @ All
US-Handel
morgen
(verkürzt): 15.30h-19.00h
2. Weihnachtstag (26.12)
gibt es in USA nicht
-> nomaler Handel 15.30h-22.00h !!!!!
Gute Nacht @ All
Schöne Weihnachtstage Euch allen!
http://www.dailymotion.com/video/x3d1yd_destinys-child-8-day…" target="_blank" rel="nofollow ugc noopener">
http://www.dailymotion.com/video/x3d1yd_destinys-child-8-day…
http://www.dailymotion.com/video/x3d1yd_destinys-child-8-day…" target="_blank" rel="nofollow ugc noopener">
http://www.dailymotion.com/video/x3d1yd_destinys-child-8-day…
Und alle am Pennen, köstlich.....
Antwort auf Beitrag Nr.: 36.264.144 von DRMARBUSE am 24.12.08 16:13:05hast du das teil hochgekauft?
vorsicht leute umsätze sind lächerlich
vorsicht leute umsätze sind lächerlich
in 2 stunden wieder bei 0,35
+ 20 % reicht für einen verkürzten
Handelstag völlig aus.
DRM.
Handelstag völlig aus.
DRM.
Also heute nochmals 20% und ich schnapp mir Montag wieder ein paar Zockershares
Antwort auf Beitrag Nr.: 36.266.201 von julic26 am 26.12.08 12:01:07jepp, wird heute up gehen....
DRM.
DRM.
wär schon klasse,wenn man hier die Tage nochmals richtig Feuer rein bringen könnte,so ne kleine Endjahresrakete würde meinem Depot nicht schaden
Wir werden sehen
Wir werden sehen
ich möchte euch in eurem optimismus nicht bremsen,aber weshalb hatt ein grossaktionär am 23 dezember dann aktien im gesamtwert von 249 dausend dollar verkauft?nachdem er diese bei fast 1 dollar gekauft hatt?
23-Dec-08 FLYNN JAMES E
Beneficial Owner
Sale at $0.52 - $0.56 per share. $249,0002
23-Dec-08 FLYNN JAMES E
Beneficial Owner
Sale at $0.52 - $0.56 per share. $249,0002
Antwort auf Beitrag Nr.: 36.268.255 von ottifant29 am 27.12.08 14:09:37teil verkauft..
hat noch immer 1,783,017 stk..
abschreibung?
oder neue investition in SLXP?
http://finviz.com/insidertrading.ashx?oc=1352546&tc=7
hat noch immer 1,783,017 stk..
abschreibung?
oder neue investition in SLXP?
http://finviz.com/insidertrading.ashx?oc=1352546&tc=7
bis wann soll der merger über die bühne gehen,wieviele neue shares werden ausgegeben?
werden sie ihr leader medikament bidil verkaufen ?
was feststeht ist das der name von nitromed ganz verschwinden wird,und in Archemix geändert wird.
über all das sollen angeblich die aktionäre entscheiden.
zu viele ungereimtheiten.
und dann der verkauf,kurz nach der meldung mit glaxo.
weckt auch kein vertrauen.
aber vielleicht könnt ihr mir diese fragen beantworten.
werden sie ihr leader medikament bidil verkaufen ?
was feststeht ist das der name von nitromed ganz verschwinden wird,und in Archemix geändert wird.
über all das sollen angeblich die aktionäre entscheiden.
zu viele ungereimtheiten.
und dann der verkauf,kurz nach der meldung mit glaxo.
weckt auch kein vertrauen.
aber vielleicht könnt ihr mir diese fragen beantworten.
Antwort auf Beitrag Nr.: 36.269.598 von ottifant29 am 28.12.08 10:35:02was erwartest du nach eine fuzion?
Antwort auf Beitrag Nr.: 36.270.233 von eula am 28.12.08 15:01:51was erwartest den du von der fusion?
- Additional Proxy Soliciting Materials (definitive) (DEFA14A)
Date : 01/05/2009 @ 4:48PM
Source : Edgar (US Regulatory)
Stock : (NTMD)
Quote : 0.41 0.0 (0.00%) @ 7:16AM
- Additional Proxy Soliciting Materials (definitive) (DEFA14A)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant x
Filed by a Party other than the Registrant o
Check the appropriate box:
o
Preliminary Proxy Statement
o
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o
Definitive Proxy Statement
x
Definitive Additional Materials
o
Soliciting Material Pursuant to §240.14a-12
NitroMed, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
x
No fee required.
o
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1)
Title of each class of securities to which transaction applies:
(2)
Aggregate number of securities to which transaction applies:
(3)
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
(4)
Proposed maximum aggregate value of transaction:
(5)
Total fee paid:
o
Fee paid previously with preliminary materials.
o
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
(1)
Amount Previously Paid:
(2)
Form, Schedule or Registration Statement No.:
(3)
Filing Party:
(4)
Date Filed:
This filing consists of the following letter that is being mailed by NitroMed, Inc. (“NitroMed”) to certain of its stockholders of record as of December 11, 2008, which is the record date for its special meeting of stockholders to be held on January 14, 2009.
NITROMED, INC.
45 HAYDEN AVENUE, SUITE 3000
LEXINGTON, MA 02421
T. 781.266.4000
F.
781.274.8080
www.nitromed.com
IMPORTANT NOTICE
January 5, 2009
Dear Valued Stockholder,
We have recently sent you proxy materials in connection with the special meeting of stockholders of NitroMed, Inc.
to be held on Wednesday, January 14, 2009. According to our latest records, we have not received your Proxy Vote for this meeting. At the special meeting, you will be asked to approve the sale of assets pursuant to the purchase and sale agreement which are described in detail in the proxy statement previously sent to you.
Your vote is very important. If you fail to vote on the asset sale, the effect will be the same as a vote against the approval of the asset sale.
The asset sale cannot be completed unless the asset sale is approved by the affirmative vote of the holders of a majority of the outstanding shares of NitroMed common stock entitled to vote.
Therefore, regardless of the number of shares you own, it is important that your vote is represented at meeting. Your vote matters to us and we need your support.
Your Board of Directors unanimously recommends that shareholders vote FOR all proposals.
We strongly encourage you to vote your shares today FOR all proposals.
Voting is easy. To ensure that your vote is recorded in time for the special shareholders meeting, please reference the telephone or Internet voting options on the enclosed form.
YOUR PARTICIPATION IS IMPORTANT - PLEASE VOTE TODAY!
If you have any questions relating to the special meeting or need assistance voting your shares, you may call our proxy solicitation agent, The Altman Group, at (800) 249-7120 (toll free).
Thank you in advance for your support .
The Board of Directors
NitroMed, Inc.
If you have already submitted the proxy form or otherwise voted, you need not take any action.
2
IMPORTANT ADDITIONAL INFORMATION AND WHERE TO FIND IT
NitroMed has filed with the SEC and mailed to its stockholders a definitive proxy statement in connection with the proposed sale of its BiDil ® and BiDil XR ™ drug business to JHP Pharmaceuticals, LLC. The proxy statement contains important information about NitroMed, the proposed sale of the BiDil and BiDil XR drug business and related matters. In addition, in connection with NitroMed’s proposed merger with Archemix Corp., NitroMed filed with the SEC a Registration Statement on Form S-4 containing a joint proxy statement/prospectus. When the Registration Statement is declared effective by the SEC, the joint proxy statement/prospectus included therein will be mailed to stockholders of NitroMed and Archemix. The joint proxy statement/prospectus will contain important information about NitroMed, Archemix, the transaction and related matters. Investors and security holders of NitroMed and Archemix are urged to read carefully both the proxy statement relating to the proposed sale of the BiDil and BiDil XR drug business and the joint proxy statement/prospectus relating to the merger, when they are available.
Investors and security holders of NitroMed will be able to obtain free copies of the proxy statement for the proposed sale of the BiDil and BiDil XR drug business and the joint proxy statement/prospectus for the proposed merger (when it is available), and other documents filed with the SEC by NitroMed through the website maintained by the SEC at www.sec.gov. In addition, investors and security holders of NitroMed will be able to obtain free copies of the proxy statement for the proposed sale of the BiDil and BiDil XR drug business and the joint proxy statement/prospectus for the proposed merger (when it is available) by contacting NitroMed, Inc., Attn: Secretary, 45 Hayden Avenue, Suite 3000, Lexington, MA 02421. Investors and security holders of Archemix will be able to obtain free copies of the joint proxy statement/prospectus for the merger (when it is available) by contacting Archemix Corp., Attn: Secretary, 300 Third Street, Cambridge, MA 02142.
NitroMed, and its directors and executive officers, may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the purchase and sale agreement with JHP Pharmaceuticals relating to the sale of the BiDil and BiDil XR drug business, and NitroMed and Archemix, and their respective directors and executive officers, may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the merger agreement with Archemix. Information regarding NitroMed’s directors and executive officers is contained in NitroMed’s Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its proxy statement dated April 16, 2008, which are filed with the SEC, and in NitroMed’s definitive proxy statement relating to the proposed sale of the BiDil and BiDil XR drug business, which was filed with the SEC on December 15, 2008. As of November 30, 2008, NitroMed’s directors and executive officers, and funds affiliated with such individuals, owned approximately 33% of NitroMed’s common stock. A more complete description of the interests of NitroMed’s directors and officers is available in the definitive proxy statement relating to the sale of the BiDil and BiDil XR drug business. In addition, information regarding Archemix’s directors and officers and a more complete description of the interests of NitroMed’s directors and officers will be available in the joint proxy statement/prospectus relating to the merger.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Statements in this document regarding the proposed sale of NitroMed’s BiDil and BiDil XR drug business to JHP Pharmaceuticals and the proposed merger between NitroMed and Archemix, and any other statement about NitroMed’s management team’s future expectations, beliefs, goals, plans or prospects, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “plans,”
3
“should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: the risk that NitroMed is unable to complete the sale of its BiDil and BiDil XR drug business, which is a condition to the closing of the merger with Archemix; the risk that NitroMed and Archemix may not be able to complete the proposed merger; and other risks and uncertainties more fully described in NitroMed’s Annual Report on Form 10-K for the year ended December 31, 2007 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, each as filed with the SEC, as well as the other filings that NitroMed makes with the SEC. Investors and stockholders are also urged to read carefully the risk factors set forth in the definitive proxy statement relating to the sale of the BiDil and BiDil XR business to JHP Pharmaceuticals and set forth in the Registration Statement and the joint proxy statement/prospectus relating to the proposed merger of NitroMed and Archemix (when it is available).
In addition, the statements in this document reflect NitroMed’s expectations and beliefs as of the date of this document. NitroMed anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while NitroMed may elect to update these forward-looking statements publicly at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing NitroMed’s views as of any date after the date of this document.
Date : 01/05/2009 @ 4:48PM
Source : Edgar (US Regulatory)
Stock : (NTMD)
Quote : 0.41 0.0 (0.00%) @ 7:16AM
- Additional Proxy Soliciting Materials (definitive) (DEFA14A)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant x
Filed by a Party other than the Registrant o
Check the appropriate box:
o
Preliminary Proxy Statement
o
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o
Definitive Proxy Statement
x
Definitive Additional Materials
o
Soliciting Material Pursuant to §240.14a-12
NitroMed, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
x
No fee required.
o
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1)
Title of each class of securities to which transaction applies:
(2)
Aggregate number of securities to which transaction applies:
(3)
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
(4)
Proposed maximum aggregate value of transaction:
(5)
Total fee paid:
o
Fee paid previously with preliminary materials.
o
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
(1)
Amount Previously Paid:
(2)
Form, Schedule or Registration Statement No.:
(3)
Filing Party:
(4)
Date Filed:
This filing consists of the following letter that is being mailed by NitroMed, Inc. (“NitroMed”) to certain of its stockholders of record as of December 11, 2008, which is the record date for its special meeting of stockholders to be held on January 14, 2009.
NITROMED, INC.
45 HAYDEN AVENUE, SUITE 3000
LEXINGTON, MA 02421
T. 781.266.4000
F.
781.274.8080
www.nitromed.com
IMPORTANT NOTICE
January 5, 2009
Dear Valued Stockholder,
We have recently sent you proxy materials in connection with the special meeting of stockholders of NitroMed, Inc.
to be held on Wednesday, January 14, 2009. According to our latest records, we have not received your Proxy Vote for this meeting. At the special meeting, you will be asked to approve the sale of assets pursuant to the purchase and sale agreement which are described in detail in the proxy statement previously sent to you.
Your vote is very important. If you fail to vote on the asset sale, the effect will be the same as a vote against the approval of the asset sale.
The asset sale cannot be completed unless the asset sale is approved by the affirmative vote of the holders of a majority of the outstanding shares of NitroMed common stock entitled to vote.
Therefore, regardless of the number of shares you own, it is important that your vote is represented at meeting. Your vote matters to us and we need your support.
Your Board of Directors unanimously recommends that shareholders vote FOR all proposals.
We strongly encourage you to vote your shares today FOR all proposals.
Voting is easy. To ensure that your vote is recorded in time for the special shareholders meeting, please reference the telephone or Internet voting options on the enclosed form.
YOUR PARTICIPATION IS IMPORTANT - PLEASE VOTE TODAY!
If you have any questions relating to the special meeting or need assistance voting your shares, you may call our proxy solicitation agent, The Altman Group, at (800) 249-7120 (toll free).
Thank you in advance for your support .
The Board of Directors
NitroMed, Inc.
If you have already submitted the proxy form or otherwise voted, you need not take any action.
2
IMPORTANT ADDITIONAL INFORMATION AND WHERE TO FIND IT
NitroMed has filed with the SEC and mailed to its stockholders a definitive proxy statement in connection with the proposed sale of its BiDil ® and BiDil XR ™ drug business to JHP Pharmaceuticals, LLC. The proxy statement contains important information about NitroMed, the proposed sale of the BiDil and BiDil XR drug business and related matters. In addition, in connection with NitroMed’s proposed merger with Archemix Corp., NitroMed filed with the SEC a Registration Statement on Form S-4 containing a joint proxy statement/prospectus. When the Registration Statement is declared effective by the SEC, the joint proxy statement/prospectus included therein will be mailed to stockholders of NitroMed and Archemix. The joint proxy statement/prospectus will contain important information about NitroMed, Archemix, the transaction and related matters. Investors and security holders of NitroMed and Archemix are urged to read carefully both the proxy statement relating to the proposed sale of the BiDil and BiDil XR drug business and the joint proxy statement/prospectus relating to the merger, when they are available.
Investors and security holders of NitroMed will be able to obtain free copies of the proxy statement for the proposed sale of the BiDil and BiDil XR drug business and the joint proxy statement/prospectus for the proposed merger (when it is available), and other documents filed with the SEC by NitroMed through the website maintained by the SEC at www.sec.gov. In addition, investors and security holders of NitroMed will be able to obtain free copies of the proxy statement for the proposed sale of the BiDil and BiDil XR drug business and the joint proxy statement/prospectus for the proposed merger (when it is available) by contacting NitroMed, Inc., Attn: Secretary, 45 Hayden Avenue, Suite 3000, Lexington, MA 02421. Investors and security holders of Archemix will be able to obtain free copies of the joint proxy statement/prospectus for the merger (when it is available) by contacting Archemix Corp., Attn: Secretary, 300 Third Street, Cambridge, MA 02142.
NitroMed, and its directors and executive officers, may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the purchase and sale agreement with JHP Pharmaceuticals relating to the sale of the BiDil and BiDil XR drug business, and NitroMed and Archemix, and their respective directors and executive officers, may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the merger agreement with Archemix. Information regarding NitroMed’s directors and executive officers is contained in NitroMed’s Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its proxy statement dated April 16, 2008, which are filed with the SEC, and in NitroMed’s definitive proxy statement relating to the proposed sale of the BiDil and BiDil XR drug business, which was filed with the SEC on December 15, 2008. As of November 30, 2008, NitroMed’s directors and executive officers, and funds affiliated with such individuals, owned approximately 33% of NitroMed’s common stock. A more complete description of the interests of NitroMed’s directors and officers is available in the definitive proxy statement relating to the sale of the BiDil and BiDil XR drug business. In addition, information regarding Archemix’s directors and officers and a more complete description of the interests of NitroMed’s directors and officers will be available in the joint proxy statement/prospectus relating to the merger.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Statements in this document regarding the proposed sale of NitroMed’s BiDil and BiDil XR drug business to JHP Pharmaceuticals and the proposed merger between NitroMed and Archemix, and any other statement about NitroMed’s management team’s future expectations, beliefs, goals, plans or prospects, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “plans,”
3
“should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: the risk that NitroMed is unable to complete the sale of its BiDil and BiDil XR drug business, which is a condition to the closing of the merger with Archemix; the risk that NitroMed and Archemix may not be able to complete the proposed merger; and other risks and uncertainties more fully described in NitroMed’s Annual Report on Form 10-K for the year ended December 31, 2007 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, each as filed with the SEC, as well as the other filings that NitroMed makes with the SEC. Investors and stockholders are also urged to read carefully the risk factors set forth in the definitive proxy statement relating to the sale of the BiDil and BiDil XR business to JHP Pharmaceuticals and set forth in the Registration Statement and the joint proxy statement/prospectus relating to the proposed merger of NitroMed and Archemix (when it is available).
In addition, the statements in this document reflect NitroMed’s expectations and beliefs as of the date of this document. NitroMed anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while NitroMed may elect to update these forward-looking statements publicly at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing NitroMed’s views as of any date after the date of this document.
Da geht doch was
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 229 | ||
| 96 | ||
| 87 | ||
| 60 | ||
| 55 | ||
| 38 | ||
| 34 | ||
| 32 | ||
| 26 | ||
| 25 |
| Wertpapier | Beiträge | |
|---|---|---|
| 19 | ||
| 19 | ||
| 19 | ||
| 18 | ||
| 18 | ||
| 17 | ||
| 17 | ||
| 16 | ||
| 15 | ||
| 14 |
